-
Mashup Score: 0Toripalimab Granted FDA Fast Track Status for Mucosal Melanoma - 3 year(s) ago
January 25, 2021 – The FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr. Luke the Role of Molecular Testing in Melanoma - 3 year(s) ago
Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Suthee Rapisuwon, MD, reviews management strategies under exploration for mucosal, acral, and uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Future of Immunotherapy in Melanoma to Focus on Overcoming Resistance, Personalizing Regimens - 4 year(s) ago
With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
.@US_FDA has granted toripalimab a fast track designation for use in the frontline treatment of patients with mucosal melanoma #melnm https://t.co/xGCKydSDYb